oa Riociguat: PATENT-1 Study

References

1. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005; 172::352–357.
   [Google Scholar]
2. Riley MS, Pórszász J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest. 1997; 111::44–50.
   [Google Scholar]
3. Chockalingam A, Gnanavelu G, Venkatesan S, Elangovan S, Jagannathan V, Subramaniam T, Alagesan R, Dorairajan S. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol. 2005; 99::91–95.
   [Google Scholar]
4. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125::580–586.
   [Google Scholar]
5. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013; 218::279–313.
   [Google Scholar]
6. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, PATENT-1 Study Group . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369::330–340.
   [Google Scholar]
7. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006; 355::2003–2011.
   [Google Scholar]
8. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci. 2009; 14::1–18.
   [Google Scholar]
9. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003; 93::96–105.
   [Google Scholar]
10. Roy B, Mo E, Vernon J, Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol. 2008; 153::1495–1504.
    [Google Scholar]
11. Priviero FB, Webb RC. Heme-dependent and independent soluble guanylate cyclase activators and vasodilatation. J Cardiovasc Pharmacol. 2010; 56::229–233.
    [Google Scholar]
12. Stasch JB, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011; 123::2263–2273.
    [Google Scholar]
13. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006; 5::755–768.
    [Google Scholar]
14. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev. 2009; 18::35–41.
    [Google Scholar]
15. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, Dingendorf A, Hackemack S, Kolosionek E, Kaulen C, Dumitrascu R, Weissmann N, Mittendorf J, Klepetko W, Seeger W, Ghofrani HA, Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008; 32::881–891.
    [Google Scholar]
16. Schymura Y, Janssen W, Stasch J-P, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT. Antifibrotic effects of riociguat in a murine model of chronic right ventricular pressure overload. Am J Respir Crit Care Med. 2012; 185::A6850.
    [Google Scholar]
17. Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, Musella F, Gargiulo P, Marciano C, Perrone-Filardi P. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60::1192–1201.
    [Google Scholar]
18. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group . Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353::2148–2157.
    [Google Scholar]
19. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group . Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119::2894–2903, [Erratum, Circulation 2011; 124(10):e279.].
    [Google Scholar]
20. Rickert V, Haefeli WE, Weiss J. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro. Pulm Pharmacol Ther. 2014; 28:2:130–137.
    [Google Scholar]
21. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27::89–95.
    [Google Scholar]
22. Galiè N, Neuser D, Muller K, Scalise A-V, Grunig E. A placebo controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). Am J Resp Crit Care Med. 2013; 187::A3530.
    [Google Scholar]
23. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62::D22–D33.
    [Google Scholar]
24. Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert MJC, Jing Z-C, Keogh AM, Langleben D, Fritsch A, Ochan Kilama M, Neuser D, Ghofrani H-A. Riociguat for the treatment of pulmonary arterial hypertension (PAH): a phase III long-term extension study (PATENT-2). Am J Respir Crit Care Med. 2013; 187::A3531.
    [Google Scholar]